Johnson & Johnson: Crohn Disease trials

The registry lists 62 Crohn Disease studies with Johnson & Johnson as lead sponsor. 16 are open to participants now and 18 have results posted.

Phase 1 2Phase 2 10Phase 3 25Phase 4 5No phase 23(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian SettingNot yet recruitingNCT07851207
• A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative ColitisNot yet recruitingNCT07848737
• A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNot yet recruitingNCT07746765
• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 4
• A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative ColitisRecruitingNCT07606339
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07577843Phase 3
• A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi ArabiaRecruitingNCT07541261
• A Study to Assess Real-world Outcomes for Long-Term Use of GuselkumabRecruitingNCT07532213
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07499232Phase 3
• A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)RecruitingNCT07310095Phase 4
• A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)RecruitingNCT07242248
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07196722Phase 2/3
• A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in GermanyRecruitingNCT07102368
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05923073Phase 3
• A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRecruitingNCT04372108
• A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical ResectionTerminatedNCT05784129Phase 3Results posted
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT05197049Phase 3Results posted
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT04673357Phase 3Results posted
• A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT04397263Phase 3Results posted
• A Study Evaluating Participants With Moderately to Severely Active Crohn's DiseaseTerminatedNCT04102111Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT03782376Phase 3Results posted
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT03466411Phase 2/3Results posted
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One YearCompletedNCT03464136Phase 3Results posted
• Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With UstekinumabCompletedNCT03107793Phase 3Results posted
• Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT02877134Phase 2Results posted
• A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedNCT01804166Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)CompletedNCT01369355Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)CompletedNCT01369342Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)CompletedNCT01369329Phase 3Results posted
• A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of RecurrenceTerminatedNCT01190839Phase 3Results posted
• A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF TherapyCompletedNCT00771667Phase 2Results posted
• A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's DiseaseCompletedNCT00265122Phase 2Results posted
• Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONICCompletedNCT00094458Phase 3Results posted
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease PatientsActive, not recruitingNCT06408935Phase 3
• A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in ChinaCompletedNCT06082986
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT05242471Phase 2
• A Study of Ustekinumab Treatment in Children With Crohn's DiseaseCompletedNCT05242458
• A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsActive, not recruitingNCT05092269Phase 3
• A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT05029921Phase 4
• A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's DiseaseWithdrawnNCT04655807Phase 2
• A Study of Infliximab in the Treatment of Chinese Children With Crohn's DiseaseCompletedNCT04312659
• A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care ProvidersTerminatedNCT04232228
• Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)CompletedNCT03942120
• Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory DiseasesCompletedNCT03606499
• Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's DiseaseCompletedNCT03495973
• An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's DiseaseNo longer availableNCT03362736
• A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative ColitisTerminatedNCT03358706Phase 1
• A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseCompletedNCT02968108Phase 1
• Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's DiseaseCompletedNCT01203631Phase 2
• The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera EndoscopyCompletedNCT01181765Phase 4
• Post Marketing Surveillance of RemicadeCompletedNCT00724529
• Remicade Infusion Management ProgramCompletedNCT00723905
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseActive, not recruitingNCT00606346
• The Crohn's Therapy, Resource, Evaluation, and Assessment Tool RegistryCompletedNCT00553176
• An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.CompletedNCT00440817
• An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's DiseaseCompletedNCT00269854Phase 2/3
• An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's DiseaseCompletedNCT00269841Phase 3
• A Long-term Safety Study of Infliximab (Remicade)CompletedNCT00261976
• A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's DiseaseCompletedNCT00207766Phase 3
• A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's DiseaseCompletedNCT00207675Phase 3
• A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's DiseaseCompletedNCT00207662Phase 3